Cell therapy · 2026
Cell therapy in China,
honestly graded.
Stem cells, immune cells (NK · CIK · DC-CIK · CAPRI), exosomes and neonatal cell banking — under one NMPA-regulated framework. China’s first approved MSC drug, four-plus CAR-T approvals, GMP-grade products at Class A hospitals. We grade the evidence honestly and decline cases where cells won’t help.
Jan 2025
First MSC drug approved
Ruibosheng (amimestrocel) — NMPA approval
NMPA, 2025
4+
NMPA-approved CAR-T
Yikaida, Carteyva, Fukerui, Yuanruida
NMPA, 2024
2,794
Registered stem-cell studies
On China Clinical Trial Registry (ChiCTR)
ChiCTR, 2024
4
Cell categories
Stem · immune · exosome · banking
Panda Touring Care
Class A
All partner facilities
NMPA-licensed GMP-grade cellular labs
NHC / NMPA
12 mo
Follow-up included
Telehealth review with operating physician
Panda Touring Care
The case
One framework,
four kinds of cells.
“Cell therapy” covers very different things — regenerative stem cells, cancer-fighting immune cells, cell-free exosomes, and the banking of a newborn’s cells for future use. China regulates all of them through one coherent structure: NMPA-approved cellular drugs plus filed clinical research at Class A hospitals.
That matters because the global cell-therapy market is full of over-promising. After earlier abuses, China deliberately reformed: legitimate treatment now happens only inside the regulated framework. In January 2025 the NMPA approved Ruibosheng — China’s first MSC drug — and four-plus CAR-T products are approved for blood cancers.
For international patients this means real access to evidence-graded protocols at licensed facilities — not ‘cell tourism.’ This hub maps every category and links to the deep dives. Panda Touring Care partners exclusively with NMPA-licensed Class A hospitals including Beijing 301, Shanghai Ruijin, Renji and Boao Lecheng.
The cluster
Six cell-therapy pathways.
Stem cells — MSC 间充质干细胞
Mesenchymal stem cells from cord, placenta, bone marrow or fat. Immune-modulating and regenerative — GVHD (NMPA-approved), osteoarthritis, autoimmune, chronic wounds.
$8.4–28k
Immune cells — NK / CIK / DC-CIK / CAPRI 免疫细胞
The body's defence cells, expanded and re-infused. Used as adjuncts in oncology and immune support via registered clinical research; CAR-T is NMPA-approved for blood cancers.
$12–35k
NK-cell therapy 自然杀伤细胞
Natural killer cells — the first line against tumour and virus-infected cells. Expanded, allogeneic-compatible, low immunogenicity. Adjunct in cancer supportive care.
$12–30k
Exosome therapy 外泌体
Nano-vesicles secreted by MSC carrying regenerative signalling cargo. A cell-free option for inflammatory and degenerative conditions; lower cost, emerging evidence.
$6–15k
CAR-T cellular therapy
Four-plus NMPA-approved products for B-cell lymphoma, ALL and multiple myeloma — at roughly one-third of US pricing.
$60–140k
Stem-cell banking 围产组织细胞储存
Cryopreserve a newborn's cord blood, cord tissue, placenta and immune cells at birth — a one-time, non-repeatable opportunity for the whole family.
$2–6k + storage
How we work
Four principles we won’t bend.
Two regulated tracks
Cellular drugs approved by NMPA (Ruibosheng MSC, CAR-T), plus filed clinical research (备案) at qualified Class A hospitals. Anything outside this framework is not legitimate — we only use licensed facilities.
Honest evidence grading
We grade every indication: strong (GVHD, CAR-T, knee OA), moderate (autoimmune, some oncology adjuncts), emerging (metabolic, neuro). We name what's investigational and decline cases where cell therapy won't help.
GMP-grade products
Every cellular product is processed in NMPA-licensed GMP labs with release testing — viability, sterility, phenotype (e.g. CD3/CD56 for immune cells), endotoxin and identity verification.
Whole-family value
Neonatal cell banking stores cord blood, cord tissue, placenta and immune cells once — low immunogenicity means stored samples can serve siblings and parents, not just the child.
We deliberately temper the marketing language common in this field. Broad “anti-ageing” and “cancer-prevention” claims for immune-cell infusions are not supported by high-quality evidence and we will say so. NMPA-approved cellular indications today: GVHD (Ruibosheng) and specific blood cancers (CAR-T). Everything else is delivered as registered clinical research or declined.
The patient pathway
Six steps from inquiry
to 12-month follow-up.
Case review
Submit medical records, imaging and current medications. A senior physician determines candidacy, recommends the cell type (stem / immune / exosome) and protocol within 5–7 business days — or tells you honestly if cell therapy isn't indicated.
Itemized quote
Receive a written quote covering cell processing, treatment, hospitalization, accommodation and coordinator. Compare 2–3 hospital options where appropriate.
M-visa & travel
We issue the hospital invitation letter (3–5 days); M-visa application runs 5–15 business days. Book flexible-date travel.
On-site collection / harvest
Consultation, baseline labs and imaging. For autologous cells: harvest from blood, marrow, fat or cord. For allogeneic / banked cells: matching and retrieval. Processing 7–14 days.
Infusion & recovery
Cell infusion under medical supervision (IV, intra-articular or intrathecal by indication). On-site recovery with monitoring; discharge when the physician clears.
12-month follow-up
Telehealth review at week 2, 6 and months 3, 6, 12 with secure imaging upload. The operating physician remains clinician of record; bilingual records throughout.
FAQ
Cell therapy in China, answered.
- What is cell therapy and what types are available in China?
- Cell therapy uses living cells — rather than drugs or surgery — to treat, repair or protect the body. China offers four broad categories: (1) Stem cells — mesenchymal stem cells (MSC) for regeneration and immune modulation, now including China's first approved MSC drug, Ruibosheng (amimestrocel, NMPA Jan 2025); (2) Immune cells — NK, CIK, DC-CIK and CAPRI cells used as adjuncts in oncology and immune support, plus NMPA-approved CAR-T for blood cancers; (3) Exosomes — extracellular vesicles secreted by stem cells, used for inflammatory and degenerative conditions; (4) Cell banking — cryopreservation of a newborn's cord blood, cord tissue, placenta and immune cells for future personal or family use.
- Is cell therapy legal and regulated in China?
- Yes, through two parallel tracks. The drug track: the NMPA approves specific cellular products as drugs — China now has an approved MSC drug (Ruibosheng) and four-plus approved CAR-T products. The clinical-research track: stem-cell and immune-cell treatments are delivered as filed clinical research (备案) at qualified Class A hospitals under National Health Commission and NMPA oversight, following the 2015 regulatory reform. Commercial 'over-the-counter' immune-cell treatment outside this framework is not permitted — a deliberate correction after earlier abuses. International patients should only use NMPA-licensed Class A facilities; Panda Touring Care partners exclusively with these.
- What's the difference between stem cells, immune cells and exosomes?
- Stem cells (MSC) self-renew and modulate inflammation — used for regeneration, autoimmune and orthopedic conditions. Immune cells (NK / CIK / DC-CIK / CAPRI / CAR-T) are the body's defence cells, expanded and re-infused to recognise and clear abnormal or cancerous cells. Exosomes are nano-sized vesicles released by stem cells that carry their signalling cargo — a cell-free option used for inflammatory and degenerative indications. They are complementary, not interchangeable; your physician recommends based on indication.
- Can foreigners receive cell therapy or bank cells in China?
- Yes. International patients access NMPA-approved cellular drugs and registered clinical research through dedicated international departments at Class A hospitals with English-speaking coordination. Cell banking (cord blood, cord tissue, placenta) is a commercial storage service available to families. Panda Touring Care manages the full pathway: case review, eligibility assessment, M-visa, on-site treatment or sample collection, and follow-up.
- How much does cell therapy cost in China?
- All-in pricing including coordinator and on-site stay: autologous MSC $8,400–$24,000; allogeneic MSC $10,000–$28,000; exosome protocols $6,000–$15,000; NK / CIK / DC-CIK immune-cell courses $12,000–$35,000; CAR-T $60,000–$140,000 (vs $400,000+ in the US). Neonatal stem-cell banking is typically $2,000–$6,000 upfront plus ~$150–$400/year storage. Pricing varies by hospital and protocol — request itemized quotes.
- Is cell therapy safe and does it actually work?
- Honest answer: evidence varies sharply by indication. Strong evidence exists for GVHD (Ruibosheng's approved indication), CAR-T in specific blood cancers, knee osteoarthritis (autologous MSC), and chronic wounds. Immune-cell adjuncts (NK / CIK / DC-CIK) show benefit as add-ons in some oncology trials but are not stand-alone cures; broad anti-ageing and cancer-prevention claims are not supported by high-quality evidence. At NMPA-licensed GMP facilities, serious adverse events in major MSC trials run below 1%. We grade evidence honestly and will tell you when a therapy is investigational.
- Where in China should I go for cell therapy?
- Top centres: Beijing 301 PLA General Hospital (cellular therapy lab); Beijing PUMC International Department; Shanghai Ruijin Hospital (haematology and stem-cell flagship); Renji Hospital Shanghai (CAR-T leader); Boao Lecheng Pilot Zone in Hainan (special regulatory zone for advanced regenerative therapies); HKU-Shenzhen Hospital (English-first). All operate NMPA-licensed cellular therapy facilities and registered research programmes.
Explore the cluster
Immune Cell Therapy
NK, CIK, DC-CIK and CAPRI cells — how they work, where they help, and the honest regulatory reality in China.
Read on immune cellsNK-Cell Therapy
Natural killer cells — the body's first responders against tumour and virus-infected cells.
Read on NK cellsStem-Cell Banking
Cord blood, cord tissue, placenta and immune-cell storage at birth — a one-time family decision.
Read on bankingExosome Therapy
Cell-free MSC-derived vesicles for inflammatory and degenerative conditions.
Read on exosomesStem Cell Therapy
The MSC therapy pillar — autologous vs allogeneic, conditions, and all-in cost.
Read on stem cellsCAR-T Therapy
Four-plus NMPA-approved CAR-T products for B-cell lymphoma, ALL and multiple myeloma.
Read on CAR-THonest candidacy
assessment, free.
Submit your records and a 30-minute video review with a senior physician will tell you straight which cell therapy — if any — can help, and what realistic outcomes look like for your condition.